Mitochondria and the future of RASopathies: the emergence of bioenergetics

J Clin Invest. 2022 Apr 15;132(8):1-5. doi: 10.1172/JCI157560.


RASopathies are a family of rare autosomal dominant disorders that affect the canonical Ras/MAPK signaling pathway and manifest as neurodevelopmental systemic syndromes, including Costello syndrome (CS). In this issue of the JCI, Dard et al. describe the molecular determinants of CS using a myriad of genetically modified models, including mice expressing HRAS p.G12S, patient-derived skin fibroblasts, hiPSC-derived human cardiomyocytes, an HRAS p.G12V zebrafish model, and human lentivirally induced fibroblasts overexpressing HRAS p.G12S or HRAS p.G12A. Mitochondrial proteostasis and oxidative phosphorylation were altered in CS, and inhibition of the AMPK signaling pathway mediated bioenergetic changes. Importantly, the pharmacological induction of this pathway restored cardiac function and reduced the developmental defects associated with CS. These findings identify a role for altered bioenergetics and provide insights into more effective treatment strategies for patients with RASopathies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Costello Syndrome* / metabolism
  • Energy Metabolism
  • Humans
  • Mice
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Signal Transduction
  • Zebrafish* / metabolism


  • Proto-Oncogene Proteins p21(ras)